belatacept (Nulojix)
in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL) - 2 receptor antagonist for induction therapy to this belatacept-based regimen.
